{"id":"NCT00566254","sponsor":"Eisai Inc.","briefTitle":"Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)","officialTitle":"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2007-12-03","resultsPosted":"2012-12-11","lastUpdate":"2013-05-13"},"enrollment":207,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy; Paediatric Partial Onset Seizures"],"interventions":[{"type":"DRUG","name":"Zonisamide","otherNames":["Zonegran"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Zonisamide","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare the safety and efficacy of zonisamide with placebo.","primaryOutcome":{"measure":"Percentage of Participants With a Decrease From Baseline in 28-day Seizure Frequency of =50%(Responder) in the Maintenance Period(LOCF)","timeFrame":"Baseline (Week -8 to Week 0), and Week 8 to Week 20","effectByArm":[{"arm":"Placebo","deltaMin":31,"sd":null},{"arm":"Zonisamide","deltaMin":50,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":43,"countries":["Belgium","Estonia","France","Hungary","Italy","Latvia","Poland","Spain","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":100},"commonTop":["Nasopharyngitis","Headache","Decreased appetite","Abdominal pain upper"]}}